Cardiogen

Not FDA-approved

Last verified: October 30, 2026

At a glance

FDA approval Not FDA-approved No record in Drugs@FDA

Randomized controlled trials 0 of 3 publications on PubMed

Registered clinical trials 0 0 active

Adverse event reports 3 2 classified as serious

Cardiogen is not an FDA-approved drug: Drugs@FDA has no record of it.
PubMed lists 3 publications mentioning it, including 0 randomized controlled trials and 2 animal-only studies.
No study registered on ClinicalTrials.gov tests it as an intervention.
FDA's adverse event system (FAERS) holds 3 reports mentioning it; 2 classified as serious. Reports do not prove causation.

Research topics

Aging 2
Prostate 2
Apoptosis 1
Cell Differentiation 1
Cellular Senescence 1
Chemokine CXCL12 1
Coculture Techniques 1
Epithelial Cells 1
Fibroblasts 1
Ghrelin 1

Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).

Regulatory status

Drugs@FDA applications

No application found in Drugs@FDA, FDA's database of approved drugs.

Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query

FDA compounding safety list

Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.

Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026

Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.

Scientific publications

All publications 3
Human (MeSH) 1
Animal only 2
Clinical trials 0
Randomized controlled trials 0
Systematic reviews & meta-analyses 0
Case reports 0
Retracted 0

Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.

Latest publications

[Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging]. Human study 2010 Advances in gerontology = Uspekhi gerontologii
Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Animal study 2009 Bulletin of experimental biology and medicine
[The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats]. Animal study 2006 Advances in gerontology = Uspekhi gerontologii

Source: PubMed (NCBI) · verified October 30, 2026

Clinical trials

No registered study on ClinicalTrials.gov lists this peptide as an intervention.

Source: ClinicalTrials.gov · verified October 30, 2026

Adverse event reports

Reports: 3
Serious: 2
With death outcome: 1

Most reported reactions

Ageusia 1
Anosmia 1
Chronic obstructive pulmonary disease 1
Contusion 1
Dysuria 1
Fluid overload 1
Fluid retention 1
Pulmonary arterial hypertension 1
Rash pruritic 1
Weight decreased 1

Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.

Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query

Change history

No changes since monitoring began on October 30, 2026.